HALDOL DECANOATE

This brand name is authorized in United States. It is also authorized in Australia, Austria, Germany, Ireland, Malta, UK.

Active ingredients

The drug HALDOL DECANOATE contains one active pharmaceutical ingredient (API):

1	Haloperidol decanoate UNII AC20PJ4101 - HALOPERIDOL DECANOATE
	Haloperidol is an antipsychotic belonging to the butyrophenones group. It is a potent central dopamine type 2 receptor antagonist, and at recommended doses, has low alpha-1 antiadrenergic activity and no antihistaminergic or anticholinergic activity.
	Read more about Haloperidol

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
HALDOL DECANOATE Solution for injection	MPI, US: SPL/Old	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
N05AD01	Haloperidol	N Nervous system → N05 Psycholeptics → N05A Antipsychotics → N05AD Butyrophenone derivatives
Discover more medicines within N05AD01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	2765M, 2766N
DE	Bundesinstitut für Arzneimittel und Medizinprodukte	02376695, 02376703, 14363060
GB	Medicines & Healthcare Products Regulatory Agency	37477, 37481
IE	Health Products Regulatory Authority	27332, 27987
MT	Medicines Authority	AA018/02703, AA018/02704, AA565/15202
US	FDA, National Drug Code	50458-253, 50458-254